AVALO THERAPEUTICS INC (AVTX) Stock Price, Quote, News and Overview
NASDAQ:AVTX - Nasdaq - US05338F3064 - Common Stock - Currency: USD
AVTX Quote, Performance and Key Statistics
NASDAQ:AVTX (4/24/2025, 8:00:00 PM)
4.88
-0.07 (-1.41%)
The current stock price of AVTX is 4.88 USD. In the past month the price decreased by -41.63%. In the past year, price decreased by -69.39%.
AVTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.82 | 319.07B | ||
| AMGN | AMGEN INC | 14.12 | 150.46B | ||
| GILD | GILEAD SCIENCES INC | 13.71 | 132.33B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698.17 | 126.60B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.14 | 65.57B | ||
| ARGX | ARGENX SE - ADR | 322.85 | 36.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.56B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.98B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.60B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 27.06B | ||
| NTRA | NATERA INC | N/A | 20.88B | ||
| BIIB | BIOGEN INC | 7.26 | 17.49B |
Related stock screener links
About AVTX
Company Profile
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. The company is headquartered in Rockville, Maryland and currently employs 19 full-time employees. The company went IPO on 2015-11-13. The firm's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Company Info
AVALO THERAPEUTICS INC
540 Gaither Road, Suite 400
Rockville MARYLAND US
CEO: Michael Cola
Employees: 19
Company Website: https://www.avalotx.com/
Investor Relations: https://ir.avalotx.com/
Phone: 14105228707
AVALO THERAPEUTICS INC / AVTX FAQ
What is the stock price of AVALO THERAPEUTICS INC today?
The current stock price of AVTX is 4.88 USD. The price decreased by -1.41% in the last trading session.
What is the ticker symbol for AVALO THERAPEUTICS INC stock?
The exchange symbol of AVALO THERAPEUTICS INC is AVTX and it is listed on the Nasdaq exchange.
On which exchange is AVTX stock listed?
AVTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AVALO THERAPEUTICS INC stock?
14 analysts have analysed AVTX and the average price target is 32.64 USD. This implies a price increase of 568.85% is expected in the next year compared to the current price of 4.88. Check the AVALO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AVALO THERAPEUTICS INC worth?
AVALO THERAPEUTICS INC (AVTX) has a market capitalization of 52.07M USD. This makes AVTX a Micro Cap stock.
How many employees does AVALO THERAPEUTICS INC have?
AVALO THERAPEUTICS INC (AVTX) currently has 19 employees.
What are the support and resistance levels for AVALO THERAPEUTICS INC (AVTX) stock?
AVALO THERAPEUTICS INC (AVTX) has a support level at 4.4 and a resistance level at 4.89. Check the full technical report for a detailed analysis of AVTX support and resistance levels.
Is AVALO THERAPEUTICS INC (AVTX) expected to grow?
The Revenue of AVALO THERAPEUTICS INC (AVTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the AVTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AVALO THERAPEUTICS INC (AVTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AVTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AVTX, evaluating the profitability, health, valuation and growth aspects
- AVALO THERAPEUTICS INC (AVTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AVALO THERAPEUTICS INC (AVTX) Sales and EPS estimates to see what analysts future expectations are.
- AVALO THERAPEUTICS INC (AVTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AVALO THERAPEUTICS INC (AVTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- AVALO THERAPEUTICS INC (AVTX) Stock Chart to make your own analysis
- AVALO THERAPEUTICS INC (AVTX) Latest news and press-releases to stay up to date.
Does AVALO THERAPEUTICS INC (AVTX) stock pay dividends?
AVTX does not pay a dividend.
When does AVALO THERAPEUTICS INC (AVTX) report earnings?
AVALO THERAPEUTICS INC (AVTX) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of AVALO THERAPEUTICS INC (AVTX)?
AVALO THERAPEUTICS INC (AVTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-164.27).
What is the Short Interest ratio of AVALO THERAPEUTICS INC (AVTX) stock?
The outstanding short interest for AVALO THERAPEUTICS INC (AVTX) is 1.03% of its float. Check the ownership tab for more information on the AVTX short interest.
AVTX Technical Analysis
AVTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AVTX. No worries on liquidiy or solvency for AVTX as it has an excellent financial health rating, but there are worries on the profitability.
AVTX Financial Highlights
Over the last trailing twelve months AVTX reported a non-GAAP Earnings per Share(EPS) of -164.27. The EPS increased by 66.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.34% | ||
| ROE | -46.84% | ||
| Debt/Equity | 0 |
AVTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to AVTX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 96.49% and a revenue growth -100% for AVTX